• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

手机动态码快速登录

手机号快速注册登录

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
194424 165 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  0 C& y* I  f- w, j
. X0 b$ Y/ G9 ?9 ]
& x- {1 x; i! o
Sub-category:
5 y  L% z+ u& ^% w* N2 `Molecular Targets
* g6 E! h4 z; ~6 l  ^( ~4 z
1 g1 a# ^4 t) w8 w1 I; K; ?, M  ?- L$ `7 A7 A8 A/ y
Category:* [& i% l2 H3 @4 L1 q, h
Tumor Biology
) U8 E% ?" E6 f: l
  P& X; ?& n$ V" f6 E- r( b
# h% k+ L# i( d' r* t/ F( xMeeting:
! z9 J! G# N& _/ w2011 ASCO Annual Meeting 8 }: q: U/ J" a, \, H
  N3 n7 z/ \1 {

" x! h8 w$ e  B$ z$ `6 @Session Type and Session Title:; j9 a/ m0 _2 m9 b( L
Poster Discussion Session, Tumor Biology
6 F$ p, t/ r  c: Z. J9 y+ |( m& |) E4 F1 ]" \' t
2 U9 V& U3 i7 [6 v1 C
Abstract No:& _# ?8 y5 F! y" l# ]; C& G; z
10517 ' j7 d  q" ?* ]( {' A) v) p4 t, G4 f0 F
* V; f& Y3 w5 f0 _# C; v
  v9 y% s2 C. ]( S
Citation:
# b$ ^# d0 {  a3 ]2 @9 {0 cJ Clin Oncol 29: 2011 (suppl; abstr 10517) " }9 B* v% y8 V9 g/ R6 ?4 R" }0 X
4 s6 m/ Y/ l0 x; h8 C6 h! ~

! Z$ B/ j0 {; p& u2 j+ mAuthor(s):
  \, d5 I1 e5 `2 A2 t, cJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
3 a8 F$ ~6 x; J- ]
0 A$ m* y! U- \/ B4 e  H( J1 a
. x  k6 x9 Z% Z6 P4 |8 q, P, d$ m4 v. n
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.& J$ K" c  R- `8 x5 n) d% y
% d" l+ `2 O, G- o/ Q9 C. h
Abstract Disclosures
" S/ c0 w) W2 Y  x. H* S8 {. T1 m) J  H) z. j# [! s5 [# i1 c
Abstract:
# V8 S/ h: \2 ^! h' j& x, x8 g+ ^. Z: C9 C7 l

, v4 a# w' {5 V: V  DBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
, h4 t* R+ _0 |0 ], l/ d& |) [' b$ {. e( E: p
1 E6 ~. h9 `) _: h) K' w6 a! X: @
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 $ Q; k" x2 _2 r) M3 Y) X
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
' z) P2 s9 L) i  |
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
, o3 v& {2 Y) i( C) r  m; c3 y; D易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。
1 b6 P  L" a5 y$ p2 O- T8 yALK一个指标医院要900多 ...
" F+ O8 J0 e: ^( j/ o. `
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?
' B. D# U% Q% y
$ A( Z5 m2 ^: u6 H  S8 T$ g现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册 手机动态码快速登录

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表